Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Merck Biopharma to Develop PharmaMar’s SCLC Drug in Japan
Merck Biopharma has obtained the exclusive rights to develop and commercialize Spain-based PharmaMar’s marine-derived drug lurbinectedin for the treatment of small cell lung cancer (SCLC) in Japan, the companies said on April 3. Under the deal, PharmaMar will receive an…
To read the full story
Related Article
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
BUSINESS
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
August 4, 2026
- Fujifilm, Taiho Forge Strategic Partnership on ADC Manufacturing
August 4, 2026
- Celltrion to Launch 1st Stelara IV Biosimilar on August 20
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…